New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 6, 2024 - Fresenius Kabi announced the FDA approval of Tyenne (tocilizumab-aazg), biosimilar to Genentech’s Actemra (tocilizumab).
Download PDF
Return to publications
